← Back to patent-cliff list
Paclitaxel Oral Solution (DAE HWA Pharmaceutical)
Tier C — Watch / tradePaclitaxel Oral Solution (DAE HWA Pharmaceutical)
韩国大化制药股份有限公司
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Tubulin
Brand：Liporaxel
Indications (approved)：胃癌
Regional status
US
临床二期
2018-07-06
EU
临床三期
2017-12-18
China
临床三期
2017-12-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paclitaxel Oral Solution (DAE HWA Pharmaceutical)?
Approved indications include: 胃癌.
When does the Paclitaxel Oral Solution (DAE HWA Pharmaceutical) patent expire?
No public expiry year is available for Paclitaxel Oral Solution (DAE HWA Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Paclitaxel Oral Solution (DAE HWA Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24